Caloric restriction of db/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism

Citations Over TimeTop 10% of 2016 papers

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of liver disease and its prevalence is a serious and growing clinical problem. Caloric restriction (CR) is commonly recommended for improvement of obesity-related diseases such as NAFLD. However, the effects of CR on hepatic metabolism remain unknown. We investigated the effects of CR on metabolic dysfunction in the liver of obese diabetic db/db mice. We found that CR of db/db mice reverted insulin resistance, hepatic steatosis, body weight and adiposity to those of db/m mice. (1)H-NMR- and UPLC-QTOF-MS-based metabolite profiling data showed significant metabolic alterations related to lipogenesis, ketogenesis, and inflammation in db/db mice. Moreover, western blot analysis showed that lipogenesis pathway enzymes in the liver of db/db mice were reduced by CR. In addition, CR reversed ketogenesis pathway enzymes and the enhanced autophagy, mitochondrial biogenesis, collagen deposition and endoplasmic reticulum stress in db/db mice. In particular, hepatic inflammation-related proteins including lipocalin-2 in db/db mice were attenuated by CR. Hepatic metabolomic studies yielded multiple pathological mechanisms of NAFLD. Also, these findings showed that CR has a therapeutic effect by attenuating the deleterious effects of obesity and diabetes-induced multiple complications.

Related Papers

• → Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver(2023)27 cited
• → Regulation of hepatic lipogenesis by plasma free fatty acids: simultaneous studies on lipoprotein secretion, cholesterol synthesis, ketogenesis and gluconeogenesis (Short Communication)(1974)49 cited
• → Evidence for a reciprocal relationship between lipogenesis and ketogenesis in hepatocytes from fed virgin and lactating rats(1978)34 cited
• → Review for "Inhibition of fatty acid synthase with <scp>FT</scp> ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with <scp>NAFLD</scp> non‐alcoholic fatty liver disease: results from two early phase randomized trials"(2020)
• → Review for "Inhibition of fatty acid synthase with <scp>FT</scp> ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with <scp>NAFLD</scp> non‐alcoholic fatty liver disease: results from two early phase randomized trials"(2020)